Adenosine-A2A Receptor Pathway in Cancer Immunotherapy

Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor.

(2021) Laurence Buisseret et al.   JOURNAL OF CLINICAL ONCOLOGY

Adenosine A2A Receptors as Biomarkers of Brain Diseases

(2021) Ana Moreira-de-Sá et al.   Frontiers in Neuroscience

Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC).

(2020) Lauren Christine Harshman et al.   JOURNAL OF CLINICAL ONCOLOGY

Lessons from the A2A Adenosine Receptor Antagonist–Enabled Tumor Regression and Survival in Patients with Treatment-Refractory Renal Cell Cancer

(2020) Michail V. Sitkovsky   Cancer Discovery

Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice

(2020) Sharmilla Devi Jayasingam et al.   Frontiers in Oncology

Tumor-derived exosomes promote angiogenesis via adenosine A2B receptor signaling

(2020) Nils Ludwig et al.   ANGIOGENESIS

Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody

(2020) Kyohei Nakamura et al.   LEUKEMIA

Sufficient numbers of anti-tumor T cells is a condition of maximal efficacy of anti-hypoxia-A2-adenosinergic drugs during cancer immunotherapy

(2020) Michail V Sitkovsky   CURRENT OPINION IN PHARMACOLOGY

Oxygenation and A2AR blockade to eliminate hypoxia/HIF-1α-adenosinergic immunosuppressive axis and improve cancer immunotherapy

(2020) Katarina Halpin-Veszeleiova et al.   CURRENT OPINION IN PHARMACOLOGY

Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy

(2020) Stephen M. Hatfield et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers.

(2019) Jason J. Luke et al.   JOURNAL OF CLINICAL ONCOLOGY

CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis

(2019) Xiao-Lu Ma et al.   Journal of Hematology & Oncology

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function

(2019) Selena Vigano et al.   Frontiers in Immunology

1206PPhase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies

(2019) J Powderly et al.   ANNALS OF ONCOLOGY

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

(2019) Lawrence Fong et al.   Cancer Discovery

Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells

(2019) Beatris Mastelic-Gavillet et al.   Journal for ImmunoTherapy of Cancer

A defect in KCa3.1 channel activity limits the ability of CD8+T cells from cancer patients to infiltrate an adenosine-rich microenvironment

(2018) Ameet A. Chimote et al.   Science Signaling

A defect in KCa3.1 channel activity limits the ability of CD8+T cells from cancer patients to infiltrate an adenosine-rich microenvironment

(2018) Ameet A. Chimote et al.   Science Signaling

Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors

(2018) Lillian L. Siu et al.   CANCER RESEARCH

Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.

(2018) Alberto Chiappori et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers

(2018) Lisa Seitz et al.   INVESTIGATIONAL NEW DRUGS

Adenosine receptors: Modulators of lipid availability that are controlled by lipid levels

(2017) Andrea Leiva et al.   MOLECULAR ASPECTS OF MEDICINE

Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma

(2017) Si-Rui Ma et al.   Molecular Cancer

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

(2016) Arabella Young et al.   CANCER CELL

Emerging concepts of T cell metabolism as a target of immunotherapy

(2016) Chih-Hao Chang et al.   NATURE IMMUNOLOGY

STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways

(2016) Bing Chen et al.   Oncotarget

Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization

(2016) K. Newick et al.   Cancer Immunology Research

Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies

(2016) Stephen Willingham et al.   Cancer Immunology Research

Immunological mechanisms of the antitumor effects of supplemental oxygenation

(2015) Stephen M. Hatfield et al.   Science Translational Medicine

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study

(2015) Colm Keane et al.   Lancet Haematology

Graft versus host disease: New insights into A 2A receptor agonist therapy

(2015) Karlie R. Jones et al.   Computational and Structural Biotechnology Journal

Immunoregulatory activity of adenosine and its role in human cancer progression

(2014) Sylvia Muller-Haegele et al.   Expert Review of Clinical Immunology

Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection

(2014) Stephen M. Hatfield et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes

(2013) Alberto L Horenstein et al.   OncoImmunology

Adenosine A2A Receptor Agonist-Mediated Increase in Donor-Derived Regulatory T Cells Suppresses Development of Graft-versus-Host Disease

(2012) K. L. Han et al.   JOURNAL OF IMMUNOLOGY

Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production

(2011) A. Clayton et al.   JOURNAL OF IMMUNOLOGY

Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

(2011) Marie Therese Armentero et al.   PHARMACOLOGY & THERAPEUTICS

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

(2010) D. Jin et al.   CANCER RESEARCH

CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice

(2010) Xiaofeng Sun et al.   GASTROENTEROLOGY

Static Magnetic Field Exposure Reproduces Cellular Effects of the Parkinson's Disease Drug Candidate ZM241385

(2010) Zhiyun Wang et al.   PLoS One

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The adenosinergic immunomodulatory drugs

(2009) Akio Ohta et al.   CURRENT OPINION IN PHARMACOLOGY

Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts

(2009) Jinkun Xi et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression

(2009) R. A. Hodgson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response

(2009) Michail V. Sitkovsky   TRENDS IN IMMUNOLOGY

Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines

(2008) Roger J. Gillespie et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak

(2008) J. C. Morote-Garcia et al.   BLOOD

Regulatory T Cells and Immune Tolerance

(2008) Shimon Sakaguchi et al.   CELL